Itanapraced

Overview

Itanapraced (CHF5074) is an orally active γ-secretase modulator and a non-steroidal anti-inflammatory derivative. Itanapraced reduces Aβ42 and Aβ40 secretion with IC 50 values of 3.6 and 18.4 μM, respectively. Itanapraced inhibits cell apoptosis of hippocampal neurons induced by oxygen and glucose deprivation (OGD). Itanapraced can be used for the research of Alzheimer's disease.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > γ-secretase | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-14399
• CAS No.: 749269-83-8
• Molecular Formula: C16H11Cl2FO2
• Molecular Weight: 325.16
• Purity: 99.37%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: 2.5 mg/mL (7.69 mM); Suspended solution; Need ultrasonic
• Availability: In-stock

Source

Original product source